ArticleDigestive diseases and sciences2025
Patients with Crohn's Disease and Ileostomy Can Respond to Upadacitinib.
Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent studies have established a role for Janus kinase (JAK) inhibitors in the management of patients with inflammatory bowel disease. However, these studies excluded patients with an ileostomy.
aimWe sought to evaluate the clinical response of patients with Crohn's disease (CD) and ileostomy who were treated with upadacitinib.
methodsThis retrospective study included patients with CD who had an ileostomy secondary to medically refractory CD and who were treated with upadacitinib. Patients who underwent ileostomy takedown and continued taking upadacitinib were analyzed separately from patients with an ileostomy throughout upadacitinib treatment duration. The primary endpoint was clinical response defined by either continuation or discontinuation of upadacitinib. The secondary endpoint was identifying variables that lead to discontinuation of upadacitinib.
resultsA total of 48 patients, between the ages of 17-70 years met our inclusion criteria of having CD, an ileostomy, and upadacitinib use after ileostomy creation. Of the 48 patients, 32 (67%) had clinical improvement in CD activity with upadacitinib use based on review of clinical documentation. Upadacitinib was discontinued in 16 patients (33%) for various reasons including refractory symptoms related to CD, deep vein thrombosis, anemia/leukopenia, insurance denial, pregnancy planning, headache/back pain, or squamous cell carcinoma of the skin.
conclusionWe evaluated the efficacy of upadacitinib in patients with CD and ileostomy. Two-thirds of our cohort experienced improvement in CD-related symptoms with upadacitinib use. Further studies are needed to evaluate if altered gastrointestinal anatomy significantly impacts absorption and efficacy of upadacitinib in patients with CD.
Indexed as
Identifiers
40515784What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.